ResultsAn equal number of psychotherapists (in total) and psychiatry residents participated in the study (47.5%), while only 10% of the respondents were board-certified psychiatrists (See Figure 1). The majority worked in general hospitals with psychiatric wards or private practice. Although 95% had no direct research involvement with MDMA, 87.5% supported further scientific studies on its therapeutic potential. Despite the fact that most respondents reported limited knowledge regarding the therapeutic use of MDMA, 67.5% believed that treatment with this substance carries risks even when conducted under medical supervision. Over 60% recognized possible positive effects of MDMA in treating mental disorders, especially when combined with psychological support, which was perceived as increasing both safety and efficacy (See Figure 2). The main barriers identified were legal regulations (60%), lack of treatment standards (60%), and insufficient training or knowledge (60%) (See Figure 3).
Disclosure of InterestA. Mechlińska: None Declared, D. Swieczkowski : None Declared, A. Kwaśny Grant / Research support from: Grants: Beckley Psytech, Compass Pathways, GH Research, MSD., M. Pastuszak Grant / Research support from: Grant / Research support from: Beckley Psytech, Compass Pathways, GH Research, MSD, W. Cubała Grant / Research support from: Wiesław Jerzy Cubała: i) Grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Compass Pathways, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, Minerva, MSD, NIH, Neumora, Novartis, Orion, Otsuka, Recognify Life Sciences, Sanofi, Servier Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GH Research, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva Advisory boards: Angelini, Celon (ended 2021), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Polpharma, Sanofi